Michael Hallek to Bridged Bicyclo Compounds, Heterocyclic
This is a "connection" page, showing publications Michael Hallek has written about Bridged Bicyclo Compounds, Heterocyclic.
Connection Strength
2.488
-
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
Score: 0.723
-
Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705.
Score: 0.656
-
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
Score: 0.179
-
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
Score: 0.177
-
Venetoclax after idelalisib: relevant progress for CLL. Blood. 2018 04 12; 131(15):1632-1633.
Score: 0.177
-
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
Score: 0.175
-
Chronic lymphocytic leukaemia. Lancet. 2018 04 14; 391(10129):1524-1537.
Score: 0.175
-
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018 02 20; 9(1):727.
Score: 0.175
-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
Score: 0.051